FindTrial
Sign In

mRNA-1273.214

BIOLOGICAL7 trials

Sponsors

ModernaTX, Inc.

Conditions

InfluenzaRSVRespiratory Syncytial VirusSARS-CoV-2

Phase 1

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
CompletedNCT05585632
ModernaTX, Inc.Influenza, RSV, SARS-CoV-2
Start: 2022-10-14End: 2024-02-28Updated: 2024-03-08

Phase 2

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
CompletedNCT04796896
ModernaTX, Inc.SARS-CoV-2
Start: 2021-03-15End: 2024-03-15Updated: 2025-06-13
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
CompletedNCT04927065
ModernaTX, Inc.SARS-CoV-2
Start: 2021-05-28End: 2023-11-17Updated: 2025-02-28
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
CompletedNCT05249829
ModernaTX, Inc.SARS-CoV-2
Start: 2022-02-16End: 2023-06-23Updated: 2024-08-09
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
TerminatedNCT05584202
ModernaTX, Inc.SARS-CoV-2
Start: 2022-09-30End: 2024-11-15Updated: 2025-11-26

Phase 3

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
CompletedNCT05330975
ModernaTX, Inc.Respiratory Syncytial Virus
Start: 2022-04-01End: 2024-11-08Updated: 2025-12-30
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
CompletedNCT05436834
ModernaTX, Inc.SARS-CoV-2
Start: 2022-06-21End: 2025-10-20Updated: 2025-11-26

Related Papers

563. Safety and Immunogenicity of mRNA-1273.815 in COVID-19 Vaccine-Naïve Children 2 Through 4 Years of Age: Results From a Phase 3, Open-Label Trial
Open Forum Infectious Diseases2026-01-01
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
Clinical Infectious Diseases2025-09-242 citations
Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age
The Journal of Infectious Diseases2025-03-223 citations
P-97. Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an Investigational Vaccine Against RSV, Given at 12 Months Following a Primary Dose in Adults Aged ≥ 50 Years
Open Forum Infectious Diseases2025-01-29
P-102. Six-Month Safety, Durability, and Cross-Neutralization of the SARS-CoV-2 XBB.1.5-Containing Vaccine
Open Forum Infectious Diseases2025-01-29
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
2024-11-2512 citations
Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.
2024-09-0121 citations
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
Nature Communications2024-08-2931 citations
Safety and Immunogenicity of an mRNA-1273 Booster in Children
Clinical Infectious Diseases2024-08-165 citations
Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults
The Journal of Infectious Diseases2024-06-1833 citations
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
2024-03-193 citations
Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.
2023-12-0540 citations
2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial
Open Forum Infectious Diseases2023-11-271 citations
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Nature Medicine2023-08-3168 citations
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.
2023-08-2320 citations
Plain Language Summary of a Clinical Trial Evaluating mRNA-1273, Moderna’s mRNA-Based COVID-19 Vaccine, in Children 6 Through 11 Years of Age
Future Virology2023-07-012 citations
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
2023-06-1950 citations
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
2022-12-0532 citations
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
New England Journal of Medicine2022-10-19135 citations
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
2022-10-06121 citations

7 more papers not shown